Tejara Capital Ltd Has $8.11 Million Stock Position in Mereo BioPharma Group plc (NASDAQ:MREO)

Tejara Capital Ltd cut its position in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 18.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,317,085 shares of the company's stock after selling 512,905 shares during the quarter. Mereo BioPharma Group accounts for 5.2% of Tejara Capital Ltd's portfolio, making the stock its 5th biggest holding. Tejara Capital Ltd owned approximately 1.49% of Mereo BioPharma Group worth $8,110,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. acquired a new stake in Mereo BioPharma Group during the fourth quarter valued at approximately $37,000. Avanza Fonder AB acquired a new stake in Mereo BioPharma Group during the fourth quarter valued at approximately $69,000. Golden State Equity Partners boosted its holdings in Mereo BioPharma Group by 247.7% during the fourth quarter. Golden State Equity Partners now owns 22,600 shares of the company's stock valued at $79,000 after purchasing an additional 16,100 shares in the last quarter. PFG Investments LLC boosted its holdings in Mereo BioPharma Group by 132.0% during the fourth quarter. PFG Investments LLC now owns 39,433 shares of the company's stock valued at $138,000 after purchasing an additional 22,433 shares in the last quarter. Finally, State Street Corp acquired a new stake in Mereo BioPharma Group during the third quarter valued at approximately $195,000. 62.83% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Mereo BioPharma Group Stock Performance

MREO stock traded down $0.18 during trading on Friday, hitting $2.38. The company had a trading volume of 1,043,861 shares, compared to its average volume of 1,006,758. The firm has a 50-day moving average price of $2.79 and a 200-day moving average price of $3.56. Mereo BioPharma Group plc has a 12 month low of $2.25 and a 12 month high of $5.02.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on MREO. Jefferies Financial Group began coverage on Mereo BioPharma Group in a report on Friday, December 6th. They set a "buy" rating and a $7.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a report on Tuesday. Lifesci Capital assumed coverage on Mereo BioPharma Group in a report on Tuesday, December 24th. They issued an "outperform" rating and a $10.00 target price on the stock. Finally, Needham & Company LLC reissued a "buy" rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a report on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $7.83.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.